GMAB's Quality Score rose 1 point on Fri, Nov 6, to 17. It closed near its high of the day.
Follow GMAB's news. Pro members can get an alert when Genmab files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 86% over the past year while the S&P 500 rose 11%.
“The increase of $576 million, or 22%, was primarily driven by higher DARZALEX and Kesimpta royalties achieved under our collaborations with J&J and Novartis”
| Profit up 53% | $631M → $963M in 2 years |
| Latest filing | 6-K, Nov 5 |
ReportThu Nov 5: a profit of $5.51 a share. Kept its outlook for the year. Past reports ›
Wed Oct 28Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
GMAB closed +9.5% that day on 4.0x normal volume.
1 more big story on GMAB in the past 12 months, for Pro members.
After its last 4 reports it closed +0.3% on average, higher 2 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Excellentfor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
GMAB is #4 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 4 |
Expected to report Tue Feb 16 (in 99 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $5.51 a share.
“The increase of $576 million, or 22%, was primarily driven by higher DARZALEX and Kesimpta royalties achieved under our collaborations with J&J and Novartis, respectively, and increased EPKINLY net product sales.”
GMAB's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
| Measure | Figure |
|---|---|
| Revenue | $4.33 |
“The increase of $480 million, or 22%, was primarily driven by higher DARZALEX and Kesimpta royalties achieved under our collaborations with J&J and Novartis, respectively.”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -0.7% | +1.7% | not yet |
| Aug 6, 2026 | +5.4% | +4.8% | +5.1% |
| May 7, 2026 | -5.5% | -2.3% | -0.6% |
Sales grew every year from 2023 to 2025, to $3.7B. It made a profit in each of the three years.
RSI 70.7, MACD above signal, above both averages. Not scored.
One trade disclosed in the last six months. The newest:
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
“The biotechnology and pharmaceutical industries generally, and the cancer drug sector specifically, are characterized by rapidly advancing technologies, evolving understanding of disease etiology, intense competition and a strong emphasis on intellectual property.”
GMAB scores 17 today, which Breakaway calls Excellent. It is #4 of 90 in Pharma by Quality Score, with 5 of 14 chart checks firing. Up 86% over the past year while the S&P 500 rose 11%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
GMAB scores 17 today, which Breakaway calls Excellent (15 to 19). That is #4 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GMAB's 17.
Expected to report Tue Feb 16, a date Breakaway expects from the company's usual timing; the company has not confirmed it. GMAB closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.